Latest Bevacizumab Stories
Today, the Mesothelioma Applied Research Foundation (Meso Foundation) released a statement from the chair of its board of directors in which it discusses imminent improvements to the current standard
Aldoxorubicin Has Now Shown Two Complete Responses, In Addition to Tumor Shrinkage, Prolonged Stable Disease, and Favorable Tolerability in Patients LOS ANGELES, May 21, 2015 /PRNewswire/
Study Did Not Meet Primary or Key Secondary Endpoints SAN DIEGO, May 20, 2015 /PRNewswire/ -- Lpath, Inc.
- Lead product candidate, VAL-083 for the treatment of glioblastoma multiforme (GBM), positioned to enter registration-directed Phase II/III clinical trials in 2H 2015 - VANCOUVER, British
CAMBRIDGE, Mass., May 14, 2015 /PRNewswire/ -- Boston Biomedical, an industry leader in the development of novel compounds
86% Response Rate Observed at Highest Dose of GEN-1 in Platinum Resistant Ovarian Cancer LAWRENCEVILLE, N.J., May 13, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a fully
VANCOUVER, British Columbia and MENLO PARK, Calif., May 7, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc.
-VAL-083 Clinical Presentation on Monday, June 1, 2015, from 1:15-4:45 p.m.
CYRAMZA Now Approved in the U.S.
- End of Dose-Escalation Confirmed - VANCOUVER, British Columbia and MENLO PARK, Calif., April 20, 2015 /PRNewswire/ -- DelMar
- A hairdresser.